US FDA Mulls Granting Regulated Industry Flexibility To Respond To Misinformation
The rapid pace inaccurate information spreads on social media may necessitate loosening some of FDA’s regulations to let sponsors respond, Commissioner Robert Califf said at J.P. Morgan Healthcare Conference. Califf also worried about how legitimate debate can undermine public confidence in FDA.
You may also be interested in...
Four years after Woodcock’s famous comments, OPDP notes it is evaluating comparative claims as indicated in a recent untitled letter. DOJ is also looking at comparative claims. New FDA guidances are in the works, but it remains unknown when they will issue.
Agency leader expects to spend about a year developing a strategy to combat misinformation. On 5 August, the agency unveiled what appears to be an early component of the initiative – a web page titled Rumor Control, with facts about the safety and components of COVID-19 vaccines.
Speakers suggest ways to eliminate barriers to biosimilar uptake, but Janssen pushes back, saying there is need to inform physicians and patients of a biosimilar's interchangeability status. Biosimilar advocates want prescriber incentives, labeling changes, and FDA education on interchangeability.